The Centre for Collaborative Drug Research invites you a Lunch ’n’ Learn Seminar to discuss potential collaborative opportunities in high-throughput and phenotypic screening with visiting scientists from UK and EU:
Dr. Iain Greig, Kosterlitz Centre for Therapeutics
Dr. Stuart McElroy, European Screening Centre
Dr. Paul Andrews, UK National Phenotypic Screening Centre
Please join us Friday Nov 6th at 12 pm – 2:00 pm
Medical Sciences Building Room 4171
University of Toronto
Please RSVP by completing this FORM
About the Speakers
Dr Paul Andrews gained a Ph.D. in Molecular Biology from the University of Sheffield. In 2007 he was recruited to a Team Leader position in the Drug Discovery Unit at the University of Dundee, where he established and then applied high content screening to discover small molecules that manipulate human embryonic stem cell fate – a multicentre collaboration including the Swedish stem cell company Cellartis AB. Paul then went on to joined Cellartis as a Team Leader tasked with developing cGMP-grade stem cell reagents and small molecules as part of a large collaborative cell therapy programme for type-1 diabetes, funded by Novo Nordisk. In 2012 he established a consultancy company Stem Cell Solutions Ltd and since 2013 he has been working with the research pooling organization Scottish Universities Life Science Alliance (SULSA) to create the National Phenotypic Screening Centre (NPSC) which opened in mid-2015.
Dr Iain Greig is a medicinal chemist from the North East of Scotland. Iain started out as a physical organic chemist at the University of St Andrews, followed by spells in biophysics at Cornell and Pharmacology at the University of Aberdeen. In 2000 he serendipitously discovered a new first-in-class drug for the treatment of rheumatoid arthritis, and later started a company (OsteoRx) to develop this; the drug was finally licensed to Johnson & Johnson late last year. In 2010 Iain teamed up with Prof Ruth Ross to found Aberdeen’s Kosterlitz Centre for Therapeutics. The two later founded a second company (Signal Pharma) to develop new drugs for the treatment of heart failure and pain. The Kosterlitz Centre has a collaborative arrangement with the Centre for Collaborative Drug Research.
Dr Stuart McElroy gained a PhD in pharmacology from Strathclyde before helping to establish the Dundee Drug Discovery Unit, a small biotech style integrated drug discovery group based within Dundee University. During this time he worked on developing new drugs for neglected tropical diseases and de – risking novel first world targets focused on value creation through the generation of small molecules with a strong IP position. Stuart is now head of biology at the European Screening Centre forming part of the European Lead Factory, a new platform for innovative drug discovery aiming to bridge the gap between large pharma and Europe’s academics and SMEs.
For any inquiries, please contact the CCDR at firstname.lastname@example.org